Neoadjuvant TRK inhibitors versus chemotherapy in advanced NTRK fusion-positive sarcomas: a real-world evidence analysis
Upfront TRK inhibition provided faster, deeper responses, avoided mutilating surgeries, and enabled curative resections. These findings support TRK inhibitors as the preferred first-line option for children with NTRK fusion-positive sarcomas.
Authors
- Fuyi Zhu (ORCID: https://orcid.org/0000-0002-5581-0081)
- Haiyan Cheng (ORCID: https://orcid.org/0000-0002-8604-2425)
- Yijin Gao (ORCID: https://orcid.org/0000-0002-7592-4115)
- Qinghua Ren (ORCID: https://orcid.org/0000-0002-3441-4514)
- Yali Han (ORCID: https://orcid.org/0000-0003-4533-922X)
- Wei Yang (ORCID: https://orcid.org/0000-0002-1584-2521)
- Hong Ying Qin (ORCID: https://orcid.org/0000-0001-7699-1355)
- Yan Su (ORCID: https://orcid.org/0009-0006-9687-9356)
- Shan Wang (ORCID: https://orcid.org/0000-0002-4562-2247)
- Yang Shen (ORCID: https://orcid.org/0000-0002-2029-3977)
- Zhiyun Zhu
- Huanmin Wang (ORCID: https://orcid.org/0000-0002-2529-1217)
- Zhenni Wang
Institutions
- Shanghai Children's Medical Center (CN)
- Beijing Children’s Hospital (CN)
- Children's Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1093/oncolo/oyaf401
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00